Promising UC drug trial halted early
NCT ID NCT01671956
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called bertilimumab in 32 adults with moderate to severe ulcerative colitis. The goal was to see if it could reduce disease activity compared to a placebo. The trial was terminated early, so results are limited and no clear benefit was established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS, ACTIVE MODERATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Afula, Israel
-
Research Site
Holon, 58100, Israel
-
Research Site
Jerusalem, 91031, Israel
-
Research Site
Jerusalem, 91120, Israel
-
Research Site
Kfar Saba, 44299, Israel
-
Research Site
Tel Aviv, 64239, Israel